A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Figures and Tables

Name: A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Figures and Tables
Creator: Brett King
Published: 2021-07-29T09:22:53.550Z
Keywords: Alopecia Areata, Janus Kinase

King, Brett

doi:10.17632/b6sct48jmb.2

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Figures and Tables

Published: 29 July 2021| Version 2 | DOI: 10.17632/b6sct48jmb.2

Contributor:

Brett King

Description

Supplementary Figures 1-7. Supplementary Tables 1-5

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Figures and Tables

Description

Files

Categories

Licence